ProteoNic Licenses Protein Expression Technology to Gilead Sciences
ProteoNic has licensed its protein expression technology, 2G UNic, to Gilead Sciences.
Technology and services provider, ProteoNic, has licensed its protein expression technology, 2G UNic, to Gilead Sciences, it was announced in a Nov. 5, 2020 press release. Financial details were not disclosed.
The protein expression technology works by improving production levels across a range of mammalian host cells and selection systems. The technology can be applied to all relevant protein classes and can be combined with other protein expression-enhancing technologies. Under the terms of the licensing agreement, Gilead will obtain non-exclusive commercial rights for the application of 2G UNic to the development of its proprietary products from mammalian cells.
“We are pleased that we can play a role in the production of Gilead’s therapeutic proteins,” said Frank Pieper, CEO of ProteoNic, in the press release. “ProteoNic’s clients consistently achieve strongly increased cell line productivity and reduced manufacturing cost in the production of their biologics. We will continue our work towards reaching the maximum production potential for our clients.”
Source: ProteoNic
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
